163 related articles for article (PubMed ID: 16191453)
1. Host, viral, and vaccine factors that determine protective efficacy induced by rotavirus and virus-like particles (VLPs).
Blutt SE; Warfield KL; O'Neal CM; Estes MK; Conner ME
Vaccine; 2006 Feb; 24(8):1170-9. PubMed ID: 16191453
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the efficacy of rotavirus VLP vaccines to a live homologous rotavirus vaccine in a pig model of rotavirus disease.
El-Attar L; Oliver SL; Mackie A; Charpilienne A; Poncet D; Cohen J; Bridger JC
Vaccine; 2009 May; 27(24):3201-8. PubMed ID: 19446192
[TBL] [Abstract][Full Text] [Related]
3. Nasal immunization of mice with a rotavirus DNA vaccine that induces protective intestinal IgA antibodies.
García-Díaz A; López-Andújar P; Rodríguez Díaz J; Montava R; Torres Barceló C; Ribes JM; Buesa J
Vaccine; 2004 Dec; 23(4):489-98. PubMed ID: 15530697
[TBL] [Abstract][Full Text] [Related]
4. Rectal immunization with rotavirus virus-like particles induces systemic and mucosal humoral immune responses and protects mice against rotavirus infection.
Parez N; Fourgeux C; Mohamed A; Dubuquoy C; Pillot M; Dehee A; Charpilienne A; Poncet D; Schwartz-Cornil I; Garbarg-Chenon A
J Virol; 2006 Feb; 80(4):1752-61. PubMed ID: 16439532
[TBL] [Abstract][Full Text] [Related]
5. Intrarectal immunization with rotavirus 2/6 virus-like particles induces an antirotavirus immune response localized in the intestinal mucosa and protects against rotavirus infection in mice.
Agnello D; Hervé CA; Lavaux A; Darniot M; Guillon P; Charpilienne A; Pothier P
J Virol; 2006 Apr; 80(8):3823-32. PubMed ID: 16571799
[TBL] [Abstract][Full Text] [Related]
6. Protective efficacy of rotavirus 2/6-virus-like particles combined with CT-E29H, a detoxified cholera toxin adjuvant.
Siadat-Pajouh M; Cai L
Viral Immunol; 2001; 14(1):31-47. PubMed ID: 11270595
[TBL] [Abstract][Full Text] [Related]
7. Efficient intranasal immunization of newborn mice with recombinant adenovirus expressing rotavirus protein VP4 against oral rotavirus infection.
Liu X; Yang T; Sun QM; Sun MS
Acta Virol; 2005; 49(1):17-22. PubMed ID: 15929394
[TBL] [Abstract][Full Text] [Related]
8. Improved characteristics and protective efficacy in an animal model of E. coli-derived recombinant double-layered rotavirus virus-like particles.
Li T; Lin H; Zhang Y; Li M; Wang D; Che Y; Zhu Y; Li S; Zhang J; Ge S; Zhao Q; Xia N
Vaccine; 2014 Apr; 32(17):1921-31. PubMed ID: 24530406
[TBL] [Abstract][Full Text] [Related]
9. Amount of maternal rotavirus-specific antibodies influence the outcome of rotavirus vaccination of newborn mice with virus-like particles.
Johansson E; Istrate C; Charpilienne A; Cohen J; Hinkula J; Poncet D; Svensson L; Johansen K
Vaccine; 2008 Feb; 26(6):778-85. PubMed ID: 18191310
[TBL] [Abstract][Full Text] [Related]
10. Human rotavirus virus-like particle vaccines evaluated in a neonatal gnotobiotic pig model of human rotavirus disease.
Azevedo MP; Vlasova AN; Saif LJ
Expert Rev Vaccines; 2013 Feb; 12(2):169-81. PubMed ID: 23414408
[TBL] [Abstract][Full Text] [Related]
11. Protection against live rotavirus challenge in mice induced by parenteral and mucosal delivery of VP6 subunit rotavirus vaccine.
Lappalainen S; Pastor AR; Malm M; López-Guerrero V; Esquivel-Guadarrama F; Palomares LA; Vesikari T; Blazevic V
Arch Virol; 2015 Aug; 160(8):2075-8. PubMed ID: 26016444
[TBL] [Abstract][Full Text] [Related]
12. Protective immunity to rotavirus-induced diarrhoea is passively transferred to newborn mice from naive dams vaccinated with a single dose of a recombinant adenovirus expressing rotavirus VP7sc.
Both GW; Lockett LJ; Janardhana V; Edwards SJ; Bellamy AR; Graham FL; Prevec L; Andrew ME
Virology; 1993 Apr; 193(2):940-50. PubMed ID: 8384761
[TBL] [Abstract][Full Text] [Related]
13. Identification of an immunodominant CD4+ T cell epitope in the VP6 protein of rotavirus following intranasal immunization of BALB/c mice.
McNeal MM; Basu M; Bean JA; Clements JD; Choi AH; Ward RL
Virology; 2007 Jul; 363(2):410-8. PubMed ID: 17337285
[TBL] [Abstract][Full Text] [Related]
14. Intranasal administration of an Escherichia coli-expressed codon-optimized rotavirus VP6 protein induces protection in mice.
Choi AH; Basu M; McNeal MM; Bean JA; Clements JD; Ward RL
Protein Expr Purif; 2004 Dec; 38(2):205-16. PubMed ID: 15555936
[TBL] [Abstract][Full Text] [Related]
15. Distribution and phenotype of rotavirus-specific B cells induced during the antigen-driven primary response to 2/6 virus-like particles administered by the intrarectal and the intranasal routes.
Di Martino C; Basset C; Ogier A; Charpilienne A; Poncet D; Kohli E
J Leukoc Biol; 2007 Oct; 82(4):821-8. PubMed ID: 17652448
[TBL] [Abstract][Full Text] [Related]
16. Immune responses and protection obtained by oral immunization with rotavirus VP4 and VP7 DNA vaccines encapsulated in microparticles.
Herrmann JE; Chen SC; Jones DH; Tinsley-Bown A; Fynan EF; Greenberg HB; Farrar GH
Virology; 1999 Jun; 259(1):148-53. PubMed ID: 10364499
[TBL] [Abstract][Full Text] [Related]
17. Distribution and phenotype of murine rotavirus-specific B cells induced by intranasal immunization with 2/6 virus-like particles.
Ogier A; Franco MA; Charpilienne A; Cohen J; Pothier P; Kohli E
Eur J Immunol; 2005 Jul; 35(7):2122-30. PubMed ID: 15948217
[TBL] [Abstract][Full Text] [Related]
18. VP6: A candidate rotavirus vaccine.
Ward RL; McNeal MM
J Infect Dis; 2010 Sep; 202 Suppl():S101-7. PubMed ID: 20684688
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of recombinant BCG expressing rotavirus VP6 as an anti-rotavirus vaccine.
Dennehy M; Bourn W; Steele D; Williamson AL
Vaccine; 2007 May; 25(18):3646-57. PubMed ID: 17339069
[TBL] [Abstract][Full Text] [Related]
20. Oral and intraperitoneal immunization with rotavirus 2/6 virus-like particles stimulates a systemic and mucosal immune response in mice.
Shuttleworth G; Eckery DC; Awram P
Arch Virol; 2005 Feb; 150(2):341-9. PubMed ID: 15578236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
